Imprimer cette page
RCT: Rivaroxaban does not have an impact on disease progression and symptoms resolution in high-risk adults with mild COVID-19.

RCT: Rivaroxaban does not have an impact on disease progression and symptoms resolution in high-risk adults with mild COVID-19.

Bibliographie
17 septembre 2021

Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19 – Clinical Infectious Diseases  

The post RCT: Rivaroxaban does not have an impact on disease progression and symptoms resolution in high-risk adults with mild COVID-19. appeared first on Links Medicus.

Lu 650 fois
Évaluer cet élément
(0 Votes)

About Author

Zouhair Souissi

Dernier de Zouhair Souissi